Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Gynecol Oncol. 2016 Feb 9;141(2):247–254. doi: 10.1016/j.ygyno.2016.02.008

Table 1.

Descriptive characteristics of the cohort stratified by histology.

Squamous cell Adenocarcinoma Neuroendocrine p-value

N (%) N (%) N (%)
All 101,240 (79.5) 24,196 (19.0) 1,896 (1.5)
Year of diagnosis <0.001
1998 8,567 (8.5) 1,752 (7.2) 130 (6.9)
1999 8,211 (8.1) 1,653 (6.8) 112 (5.9)
2000 8,138 (8.0) 1,695 (7.0) 126 (6.7)
2001 7,744 (7.7) 1,623 (6.7) 118 (6.2)
2002 7,440 (7.4) 1,626 (6.7) 138 (7.3)
2003 6,982 (6.9) 1,529 (6.3) 141 (7.4)
2004 6,848 (6.8) 1,585 (6.6) 118 (6.2)
2005 6,894 (6.8) 1,633 (6.8) 133 (7.0)
2006 6,864 (6.8) 1,732 (7.2) 135 (7.1)
2007 6,884 (6.8) 1,746 (7.2) 129 (6.8)
2008 6,869 (6.8) 1,820 (7.5) 162 (8.5)
2009 6,898 (6.8) 1,985 (8.2) 142 (7.5)
2010 6,513 (6.4) 1,922 (7.9) 144 (7.6)
2011 6,388 (6.3) 1,895 (7.8) 168 (8.9)
Age <0.001
<30 5,410 (5.3) 1,291 (5.3) 213 (11.2)
30–39 20,677 (20.4) 6,055 (25.0) 377 (19.9)
40–49 27,069 (26.7) 6,926 (28.6) 409 (21.6)
50–59 20,850 (20.6) 4,343 (18.0) 377 (19.9)
60–69 13,961 (13.8) 2,754 (11.4) 259 (13.7)
≥70 13,273 (13.1) 2,827 (11.7) 261 (13.8)
Race <0.001
White 63,615 (62.8) 17,992 (74.4) 1,296 (68.4)
Black 18,444 (18.2) 2,124 (8.8) 293 (15.5)
Hispanic 13,237 (13.1) 2,601 (10.8) 195 (10.3)
Other 4,642 (4.6) 1,141 (4.7) 102 (5.4)
Unknown 1,302 (1.3) 338 (1.4) 10 (0.5)
Insurance status <0.001
Commercial 45,845 (45.3) 15,057 (62.2) 1,006 (53.1)
Medicare 18,452 (18.2) 3,746 (15.5) 366 (19.3)
Medicaid 19,791 (19.6) 2,598 (10.7) 270 (14.2)
Uninsured 10,978 (10.8) 1,542 (6.4) 152 (8.0)
Other 1,001 (1.0) 241 (1.0) 11 (0.6)
Unknown 5,173 (5.1) 1,012 (4.2) 91 (4.8)
Region <0.001
Northeast 18,606 (18.4) 4,624 (19.1) 361 (19.0)
Midwest 22,946 (22.7) 5,644 (23.3) 391 (20.6)
South 42,071 (41.6) 9,105 (37.6) 758 (40.0)
West 17,617 (17.4) 4,823 (19.9) 386 (20.4)
Location <0.001
Metropolitan 77,896 (76.9) 18,882 (78.0) 1,512 (79.8)
Urban 15,965 (15.8) 3,439 (14.2) 265 (14.0)
Rural 1,924 (1.9) 384 (1.6) 35 (1.9)
Unknown 5,455 (5.4) 1,491 (6.2) 84 (4.4)
Hospital type <0.001
Community cancer program 8,222 (8.1) 1,582 (6.5) 108 (5.7)
Comprehensive community cancer program 46,489 (45.9) 11,890 (49.1) 901 (47.5)
Academic 43,997 (43.5) 10,170 (42.0) 856 (45.2)
Other 2,532 (2.5) 554 (2.3) 31 (1.6)
Stage <0.001
IA (IA, IA1, IA2) 15,408 (15.2) 4,185 (17.3) 49 (2.6)
IB (IB, IB1, IB2, INOS) 29,461 (29.1) 10,592 (43.8) 519 (27.4)
IIA (IIA, IIA1, IIA2) 929 (0.9) 245 (1.0) 14 (0.7)
IIB (IIB, IINOS) 18,146 (17.9) 2,500 (10.3) 187 (9.9)
IIIA 1,531 (1.5) 236 (1.0) 24 (1.3)
IIIB 18,938 (18.7) 2,248 (9.3) 380 (20.0)
IVA 2,924 (2.9) 337 (1.4) 55 (2.9)
IVB 6,017 (5.9) 1,424 (5.9) 447 (23.6)
IVNOS 1,042 (1.0) 274 (1.1) 64 (3.4)
Unknown 6,844 (6.8) 2,155 (8.9) 157 (8.3)
Primary treatment <0.001
Surgery 48,855 (48.3) 16,462 (68.0) 716 (37.8)
Radiation 36,404 (36.0) 4,949 (20.5) 710 (37.5)
No surgery or radiation 6,528 (6.5) 1,493 (6.2) 347 (18.3)
Unknown 9,453 (9.3) 1,292 (5.3) 123 (6.5)